Literature DB >> 24256032

Trichomonas vaginalis flavin reductase 1 and its role in metronidazole resistance.

David Leitsch1, Brian D Janssen, Daniel Kolarich, Patricia J Johnson, Michael Duchêne.   

Abstract

The enzyme flavin reductase 1 (FR1) from Trichomonas vaginalis, formerly known as NADPH oxidase, was isolated and identified. Flavin reductase is part of the antioxidative defence in T. vaginalis and indirectly reduces molecular oxygen to hydrogen peroxide via free flavins. Importantly, a reduced or absent flavin reductase activity has been reported in metronidazole-resistant T. vaginalis, resulting in elevated intracellular oxygen levels and futile cycling of metronidazole. Interestingly, FR1 has no close homologue in any other sequenced genome, but seven full-length and three truncated isoforms exist in the T. vaginalis genome. However, out of these, only FR1 has an affinity for flavins, i.e. FMN, FAD and riboflavin, which is high enough to be of physiological relevance. Although there are no relevant changes in the gene sequence or any alterations of the predicted FR1-mRNA structure in any of the strains studied, FR1 is not expressed in highly metronidazole-resistant strains. Transfection of a metronidazole-resistant clinical isolate (B7268), which does not express any detectable amounts of FR, with a plasmid bearing a functional FR1 gene nearly completely restored metronidazole sensitivity. Our results indicate that FR1 has a significant role in the emergence of metronidazole resistance in T. vaginalis.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24256032      PMCID: PMC4437529          DOI: 10.1111/mmi.12455

Source DB:  PubMed          Journal:  Mol Microbiol        ISSN: 0950-382X            Impact factor:   3.501


  33 in total

Review 1.  Trichomonads, hydrogenosomes and drug resistance.

Authors:  J Kulda
Journal:  Int J Parasitol       Date:  1999-02       Impact factor: 3.981

2.  Trichomonas vaginalis: NADH oxidase activity.

Authors:  M Tanabe
Journal:  Exp Parasitol       Date:  1979-08       Impact factor: 2.011

Review 3.  Clinical and microbiological aspects of Trichomonas vaginalis.

Authors:  D Petrin; K Delgaty; R Bhatt; G Garber
Journal:  Clin Microbiol Rev       Date:  1998-04       Impact factor: 26.132

4.  The role of catalytic superoxide formation in the O2 inhibition of nitroreductase.

Authors:  R P Mason; J L Holtzman
Journal:  Biochem Biophys Res Commun       Date:  1975-12-15       Impact factor: 3.575

5.  Disrupted intracellular redox balance of the diplomonad fish parasite Spironucleus vortens by 5-nitroimidazoles and garlic-derived compounds.

Authors:  C F Williams; D Lloyd; D Kolarich; K Alagesan; M Duchêne; J Cable; D Williams; D Leitsch
Journal:  Vet Parasitol       Date:  2012-05-19       Impact factor: 2.738

6.  Reduction of nitroimidazole derivatives by hydrogenosomal extracts of Trichomonas vaginalis.

Authors:  N Yarlett; T E Gorrell; R Marczak; M Müller
Journal:  Mol Biochem Parasitol       Date:  1985-01       Impact factor: 1.759

7.  Metronidazole-resistant clinical isolates of Trichomonas vaginalis have lowered oxygen affinities.

Authors:  N Yarlett; N C Yarlett; D Lloyd
Journal:  Mol Biochem Parasitol       Date:  1986-05       Impact factor: 1.759

8.  Treatment of metronidazole-resistant Trichomonas vaginalis.

Authors:  Linda M Goldman; Jacqueline A Upcroft; Kimberly Workowski; Andrea Rapkin
Journal:  Sex Health       Date:  2009-12       Impact factor: 2.706

9.  Draft genome sequence of the sexually transmitted pathogen Trichomonas vaginalis.

Authors:  Jane M Carlton; Robert P Hirt; Joana C Silva; Arthur L Delcher; Michael Schatz; Qi Zhao; Jennifer R Wortman; Shelby L Bidwell; U Cecilia M Alsmark; Sébastien Besteiro; Thomas Sicheritz-Ponten; Christophe J Noel; Joel B Dacks; Peter G Foster; Cedric Simillion; Yves Van de Peer; Diego Miranda-Saavedra; Geoffrey J Barton; Gareth D Westrop; Sylke Müller; Daniele Dessi; Pier Luigi Fiori; Qinghu Ren; Ian Paulsen; Hanbang Zhang; Felix D Bastida-Corcuera; Augusto Simoes-Barbosa; Mark T Brown; Richard D Hayes; Mandira Mukherjee; Cheryl Y Okumura; Rachel Schneider; Alias J Smith; Stepanka Vanacova; Maria Villalvazo; Brian J Haas; Mihaela Pertea; Tamara V Feldblyum; Terry R Utterback; Chung-Li Shu; Kazutoyo Osoegawa; Pieter J de Jong; Ivan Hrdy; Lenka Horvathova; Zuzana Zubacova; Pavel Dolezal; Shehre-Banoo Malik; John M Logsdon; Katrin Henze; Arti Gupta; Ching C Wang; Rebecca L Dunne; Jacqueline A Upcroft; Peter Upcroft; Owen White; Steven L Salzberg; Petrus Tang; Cheng-Hsun Chiu; Ying-Shiung Lee; T Martin Embley; Graham H Coombs; Jeremy C Mottram; Jan Tachezy; Claire M Fraser-Liggett; Patricia J Johnson
Journal:  Science       Date:  2007-01-12       Impact factor: 47.728

10.  Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis.

Authors:  S N Moreno; R Docampo
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

View more
  22 in total

Review 1.  Strategies for Prevention and Treatment of Trichomonas vaginalis Infections.

Authors:  Kawthar Bouchemal; Christian Bories; Philippe M Loiseau
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

2.  A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in Trichomonas vaginalis.

Authors:  Keonte J Graves; Jan Novak; W Evan Secor; Patricia J Kissinger; Jane R Schwebke; Christina A Muzny
Journal:  Parasitology       Date:  2020-07-30       Impact factor: 3.234

3.  Detection of metronidazole resistance in Trichomonas vaginalis using uncultured vaginal swabs.

Authors:  Bongekile Ngobese; Ravesh Singh; Khine Swe Swe- Han; Partson Tinarwo; Nonkululeko Mabaso; Nathlee S Abbai
Journal:  Parasitol Res       Date:  2022-06-03       Impact factor: 2.383

4.  Effect of the Symbiosis with Mycoplasma hominis and Candidatus Mycoplasma Girerdii on Trichomonas vaginalis Metronidazole Susceptibility.

Authors:  Valentina Margarita; Le Chi Cao; Nicholas P Bailey; Thuy Ha Thi Ngoc; Thi Minh Chau Ngo; Phuong Anh Ton Nu; Nicia Diaz; Daniele Dessì; Robert P Hirt; Pier Luigi Fiori; Paola Rappelli
Journal:  Antibiotics (Basel)       Date:  2022-06-16

5.  Gold(I) Phosphine Derivatives with Improved Selectivity as Topically Active Drug Leads to Overcome 5-Nitroheterocyclic Drug Resistance in Trichomonas vaginalis.

Authors:  Yukiko Miyamoto; Shubhangi Aggarwal; Jeff Joseph A Celaje; Sozaburo Ihara; Jonathan Ang; Dmitry B Eremin; Kirkwood M Land; Lisa A Wrischnik; Liangfang Zhang; Valery V Fokin; Lars Eckmann
Journal:  J Med Chem       Date:  2021-05-11       Impact factor: 8.039

Review 6.  Recent Advances in the Trichomonas vaginalis Field.

Authors:  David Leitsch
Journal:  F1000Res       Date:  2016-02-11

7.  Metabolomic profiling and stable isotope labelling of Trichomonas vaginalis and Tritrichomonas foetus reveal major differences in amino acid metabolism including the production of 2-hydroxyisocaproic acid, cystathionine and S-methylcysteine.

Authors:  Gareth D Westrop; Lijie Wang; Gavin J Blackburn; Tong Zhang; Liang Zheng; David G Watson; Graham H Coombs
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

8.  CRISPR/Cas9-mediated gene modification and gene knock out in the human-infective parasite Trichomonas vaginalis.

Authors:  Brian D Janssen; Yi-Pei Chen; Brenda M Molgora; Shuqi E Wang; Augusto Simoes-Barbosa; Patricia J Johnson
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

Review 9.  Drug Resistance in the Microaerophilic Parasite Giardia lamblia.

Authors:  David Leitsch
Journal:  Curr Trop Med Rep       Date:  2015

10.  Leukocyte Lysis and Cytokine Induction by the Human Sexually Transmitted Parasite Trichomonas vaginalis.

Authors:  Frances Mercer; Fitz Gerald I Diala; Yi-Pei Chen; Brenda M Molgora; Shek Hang Ng; Patricia J Johnson
Journal:  PLoS Negl Trop Dis       Date:  2016-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.